Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Brazilian JV looks to tap plant-based manufacturing system for biosimilars

The Brazilian JV will focus on biosimilars and build a manufacturing facility

Biologic manufacturer PlantForm and PharmaPraxis have established a joint venture to develop, manufacture and commercialize biosimilar versions of six key biopharma treatments.

Related news

News in brief

Sartorius Stedim Biotech has attributed strong sales and order growth in the second quarter 2014 to recent acquisitions and demand for single-use products.

Timescales and sourcing comparator biologics are the biggest challenges for biopharmas running biosimilars studies, says an expert.

Interest in creating alternatives to Protein A has waned in light of more viable cost-saving opportunities in bioprocessing, such as single-use adoption, says Repligen.

3P Biopharmaceuticals has raised funds and announced plans to invest in its manufacturing capabilities to meet the needs of international clients.

Global Industry News

Feature

Jay-Z and Scarface: pharma staff’s anonymous Wikipedia interests from in-PharmaTechnologist.com

Big pharma employees are among the brightest minds in the world, and data released yesterday on their Wikipedia use shows their interests spread beyond drug development into lighter fare.

Onyx contracted for API R&D and manufacturing by UK cancer charity from Outsourcing-Pharma.com

Onyx Scientific has been contracted to develop and manufacture APIs for clinical trials by charitable group Cancer Research UK.

Generics: change in pill shape makes patients 66% more likely to quit from in-PharmaTechnologist.com

Switching patients to generic pills of a different shape and colour increases the chances they will end their course of medicine early, according to research.

USFDA approves Novasep facilities for kinase inhibitor contract from Outsourcing-Pharma.com

Novasep has received the regulatory nod to manufacture a kinase inhibitor new molecular entity (NME) following pre-approval inspections at two facilities in France.

Lilly swaps dry powders for insulin at Indiana site in post-patent shake-up from in-PharmaTechnologist.com

Patent expiration and a large molecule pipeline has prompted Eli Lilly to repurpose a solid oral dose plant in Indiana.

European Pharmacopoeia plans revisions of elemental impurities guideline from in-PharmaTechnologist.com

As the International Conference on Harmonisation (ICH) signs off on a new tripartite guideline related to elemental impurities, the European Pharmacopoeia Commission will revise its texts to ensure consistency. 

Spotlight

US venture capital investors continue to back biotech

US venture capital investors continue to back biotech

Biopharma firms continued to attract US venture capital investment in Q1 according to new analysis by PricewaterhouseCoopers...

EMA revises what it classifies as advanced-therapy treatments

EMA revises what it classifies as advanced-therapy treatments

The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products...

BioOutsource targets biosimilars testing growth with new US lab

BioOutsource targets biosimilars testing growth with new US lab

US demand for biosimilars testing will grow substantially in the next few years according to BioOutsource, which...

Rentschler expands manufacturing capacity with stainless steel

Rentschler expands manufacturing capacity again, this time with stainless steel

The Laupheim, Germany-based CMO (contract manufacturing organization) Rentschler Biotechnologie has invested €24m ($33m) to build a twin...

EU green lights first insulin biosimilar from Lilly, BI

EU green lights first insulin biosimilar from Lilly, BI

The EU’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion and recommended granting...